Nalidixic acid -resistant Salmonella typhi (NARST) was first isolated in Viet Nam in 1993. Analysis of the quinolone resistance-determining region of gyrA in 20 NARST isolates by polymerase chain reaction and single-stranded conformational polymorphism yielded two novel patterns: pattern II corresponding to a point mutation at nucleotide 87 Asp r Gly (n Å 17), and pattern III corresponding to a point mutation at nucleotide 83 Ser r Phe (n Å 3). In trials of short-course ofloxacin therapy for uncomplicated typhoid, 117 (78%) of 150 patients were infected with multidrug-resistant S. typhi, 18 (15%) of which were NARST. The median time to fever clearance was 156 hours (range, 30 -366 hours) for patients infected with NARST and 84 hours (range, 12 -378 hours) for those infected with nalidixic acid -susceptible strains (P õ .001). Six (33.3%) of 18 NARST infections required retreatment, whereas 1 (0.8%) of 132 infections due to susceptible strains required retreatment (relative risk Å 44; 95% confidence interval Å 5.6 -345; P õ .0001). We recommend that short courses of quinolones not be used in patients infected with NARST.
Typhoid is a major cause of morbidity in tropical countries.
nolone antibiotics have become the treatment of choice for multidrug-resistant typhoid fever. Indeed, they are the only The development of antibiotic resistance in Salmonella typhi poses the considerable threat of increased mortality and moreffective orally active drugs for this common infection. Resistance to these compounds will therefore have serious public bidity to many communities of the world. In southern Viet Nam, multidrug resistance in S. typhi had become established health consequences, particularly in areas where typhoid fever is endemic. We report the emergence of nalidixic acid resisby late 1992 and early 1993 [1 -3] . These multidrug-resistant S. typhi isolates were resistant to the usual first-line antibiotics, tance in isolates of S. typhi in southern Viet Nam and the effect of this resistance on the response to treatment with short chloramphenicol, ampicillin, and co-trimoxazole, but remained fully susceptible to the fluoroquinolones and third-generation courses of fluoroquinolones. cephalosporins.
Quinolone resistance in other bacteria is usually associated To reduce cost and possible toxicity, courses of fluoroquinowith mutations of the target site, DNA gyrase, most commonly lones shorter than 1 week have been evaluated in patients with in the quinolone resistance -determining region (QRDR) of the mild-to-moderate typhoid fever. Studies conducted in Viet Nam A subunit [7] . In Salmonella typhimurium, resistance has been have shown that courses of treatment as short as 2 days are associated with a mutation in the gyrA gene, giving rise to ú90% effective [2 -5] , and detailed observations of children amino acid changes at serine 83 and aspartic acid 87 [8 -11] . receiving this short-course treatment have shown no apparent Single-stranded conformational polymorphism (SSCP) analysis short-or longer-term adverse effects [6] . Thus, the fluoroqui- [12] has been used to demonstrate mutations in gyrA of a number of bacterial species including Mycobacterium tuberculosis and Staphylococcus aureus [13, 14] . This technique is based on the differential mobility of single-stranded DNA in of S. typhi type A, NASST from Viet Nam, and other NASST by using a commercially available silver staining kit (Silver Sequence; Promega Biotech, Madison, WI). PCR products and NARST serotypes [9] .
were purified by binding to streptavidin-coated magnetic beads (Dynal, Oslo, Norway) for direct sequencing of the DNA with Methods use of Sequenase 2.0 (United States Biochemical Corporation).
Studies of short-course treatment of typhoid fever. Since Prospective diagnostic and treatment studies of typhoid fever have been in progress at the Centre for Tropical Diseases, Ho
October 1993, a series of studies of short-course ofloxacin therapy in adults and children with mild-to-moderate typhoid Chi Minh City, Viet Nam, since 1992. The hospital is a 500-bed referral center for patients with infectious diseases who fever have been in progress at the Centre for Tropical Diseases [5, 16] . Patients with blood culture -confirmed, uncomplicated reside in Ho Chi Minh City and the southern provinces of Viet Nam.
typhoid fever have been recruited for open randomized comparisons of ofloxacin given orally for 2 or 3 days. Microbiological methods. All isolates of S. typhi were from blood and were identified with use of specific antisera (WellAdults received ofloxacin either at a dosage of 10 mg/kg body weight in two daily divided doses for 3 days or 15 come Diagnostics, Dartford, UK) and with standard biochemical tests. Antibiotic susceptibilities were determined at the time mg/kg body weight in two daily divided doses for 2 days. Children were given ofloxacin at a dosage of 15 mg/kg body of isolation by the modified Kirby-Bauer disk diffusion method [15] with disks containing ampicillin (10 mg), chloramphenicol weight in two daily divided doses for either 2 or 3 days. Clinical failure was defined as failure to clear fever 7 days after the (30 mg), trimethoprim-sulfamethoxazole (TMP-SMZ) (1.25/ 23.75 mg), ceftriaxone (30 mg) and ofloxacin (5 mg). Multidrugstart of treatment in association with persistence of symptoms and signs or the development of severe or complicated enteric resistant strains were defined as those resistant to ampicillin, chloramphenicol, and TMP-SMZ.
fever. Repeated blood cultures were performed 48 hours after the last dose of ofloxacin was given and on day 7 if the patient Isolates from these treatment studies, which had been stored on nutrient agar slopes at room temperature or on bacterial was still febrile. Patients for whom treatment failed clinically were retreated with a further course of ofloxacin at the discrepreservers at 020ЊC, were then tested retrospectively for susceptibility to nalidixic acid. This testing included isolates from tion of the attending physician or pediatrician. Microbiological treatment failure was defined as a second positive blood culture, a study performed between December 1992 and June 1993, in which a 5-day course of oral ofloxacin was compared with a with the second isolate of S. typhi having the same antibiotic susceptibility pattern as the initial isolate after the completion 3-day course of intravenous ceftriaxone in adults with blood culture -confirmed, uncomplicated typhoid fever [2] , as well of treatment or within a 6-week follow-up period. Statistical methods. The clinical features and response to as isolates from studies of short-course ofloxacin treatment in adults and children between October 1993 and December 1994 treatment of patients with NASST and NARST isolates and the laboratory features of the isolates were compared by using [5, 16] . All S. typhi isolates recovered from blood cultures at the Centre for Tropical Diseases during 1995 were tested for Student's t test or analysis of variance. The Mann-Whitney U test was used for nonnormally distributed data. Proportions susceptibility to nalidixic acid. The MICs of ofloxacin and nalidixic acid were measured by an agar plate incorporation were compared with use of the x 2 test with Yates' correction or Fisher's exact test. Fever clearance times were compared method [17] to select NASST and NARST isolates from these studies. Escherichia coli ATCC (American Type Culture Colon the basis of survival analysis by using the Kaplan-Meier plot and logrank test and relative risk calculation. The statistical lection) 25922 was used as a control strain.
PCR, SSCP, and DNA sequencing. Twenty NARST and package SPSS for Windows version 6.1.1 (SPSS, Inc., Chicago) was used for these analyses. three NASST isolates of S. typhi were studied. S. typhi type A was purchased from the Division of Enteric Pathogens, Central Public Health Laboratory, Colindale, London. All other Salmonella strains have been described previously [9, 11] .
Results DNA prepared from bacterial strains [18] was amplified by PCR with use of the oligonucleotide primers P1 (3-TGTCCG-S. typhi isolates. Of the 41 isolates of S. typhi isolated in the first study, performed between December 1992 and June AGATGGCCTGAAGC-5) and biotinylated P2BIO (5-TAC-CGTCATAGTTATCCACG-3), described by Griggs et al. [9] .
1993 [2] , 26 (63%) were multidrug resistant, but none was resistant to nalidixic acid. This is a significantly lower proporThe amplified products were stored at 4ЊC until they were used for SSCP or DNA sequencing. SSCP was performed by using tion of multidrug-resistant strains than were recovered from a comparable group of patients in subsequent years (P Å .043). MDE high resolution gel (FMC Bioproducts, Rockland, ME) according to the manufacturer's instructions, except that 2 mL
In the short-course treatment studies performed between October 1993 and December 1994 [5, 16] , there were 150 isolates of PCR product was loaded onto the gel in 4 mL of formamide loading buffer, and visualization of DNA bands was achieved of S. typhi, including 117 multidrug-resistant strains (78%), of / 9c40$$de09 11-11-97 17:20:51 cidas UC: CID nucleotide 283 gave rise to the codon GAA (glutamic acid), times among the patients with NARST isolates were nearly twice as long as those among the patients with NASST isolates, whereas S. typhi contained the codon GGA at this position (glycine). The type A control strain of S. typhi gave the same 156 hours (interquartile range, 83 -242 hours; absolute range, 30 -366 hours) vs. 84 hours (interquartile range, 66 -108 hours; sequence for this region of the QRDR of gyrA as the nalidixic acid -susceptible strain of S. typhi TY84 from Viet Nam, conabsolute range, 12 -378 hours), respectively (P õ .001). Figure  3 shows a Kaplan-Meier plot for a comparison of fever clearfirming the difference in the SSCP patterns. Two isolates that gave SSCP pattern II (TY66 and CT48) and two isolates that ance between the two groups. There were 13 clinical failures: nine among the 18 patients with NARST isolates (overall failgave pattern III (5182 and 5214) were chosen for DNA sequencing. Pattern II isolates had a point mutation at codon 87 ure rate, 50%) and four among the 132 patients with NASST strains (overall failure rate, 3.1%) (RR, 16.5; 95% CI, 5.7 -(A to G), substituting glycine for aspartic acid, and pattern III had a point mutation at codon 83 (C to T), substituting 48.1; P õ .0001). Only one of the clinical failures was also a microbiological failure, and this failure occurred in the NARST phenylalanine for serine ( figure 2) .
Studies of short-course treatment of typhoid fever. The degroup. Retreatment in these cases of clinical failure with a further mographic and clinical features of the patients infected with NASST and NARST strains are shown in table 2. The only course of ofloxacin was considered necessary by the attending physician for one (0.8%) of the 132 patients with an NASST difference was that patients with NARST isolates were significantly younger. The response to ofloxacin treatment was conisolate and six (33.3%) of the 18 patients with NARST isolates (RR Å 44; 95% CI Å 56 -345; P õ .0001). All S. typhi isolates, siderably worse in patients with NARST infections than in those with NASST infections. The median fever clearance tested at the time of isolation by disk diffusion, were found to / 9c40$$de09 11-11-97 17:20:51 cidas UC: CID
The MICs of ofloxacin for 18 of the NARST isolates were slightly higher than those for the 160 susceptible strains but still below the recommended breakpoint (2 -8 mg/mL) [26] . However, ''susceptible'' infections with these strains responded poorly to short-course treatment with ofloxacin. The treatment failure rate among patients with NARST isolates was 50%, whereas it was õ5% if the isolate was nalidixic acid susceptible. Although the in vivo susceptibility of S. typhi can generally be predicted by the in vitro susceptibility, there are well-known exceptions, such as gentamicin. The third-generation cephalosporins are also not as active in vivo as the in vitro data would suggest. The results of the present study suggest that the response of salmonella infections to treatment with The target site of the fluoroquinolones, DNA gyrase, is made up of two subunits-A and B-coded for by gyrA and gyrB genes. The amino acid sequence of the QRDR of gyrA has been be susceptible to ofloxacin. Nalidixic-acid susceptibility testing shown to be conserved in several bacterial species ranging from was performed at a later date; therefore, the results were not E. coli and nonenteric salmonellae to staphylococci and mycoavailable at the time the decision concerning retreatment was bacteria [7] . The nucleic acid sequence reported herein demonmade. No relapses were subsequently documented.
strates that this finding is also true for S. typhi. The results of our analysis of amplified DNA fragments of the QRDR of gyrA Discussion by use of SSCP and DNA sequencing revealed two mutations in nalidixic acid-resistant strains of S. typhi from Viet Nam, as Multidrug-resistant typhoid is an important problem in tropical countries. It is endemic in Viet Nam and has the potential for compared with a standard strain of NASST (pattern I, figure 1 ). Pattern II (Ser83 r Phe) was found in 17 of 20 of the examined epidemic spread [3] . Until recently, infections with multidrugresistant S. typhi have remained uniformly susceptible to the strains, and pattern III (Asp87 r Gly) was found in 3 of 20 strains, confirming the role of these mutations in quinolone resisquinolones and third-generation cephalosporin antibiotics, although the clinical response to the cephalosporins is signifitance in S. typhi. Similar mutations have been reported in 12 NARST isolates from southern India [27] . Nine of these isolates cantly inferior [1, 2] . The quinolones have proved remarkably effective when given for 5 and 7 days and retain excellent cure had the substitution Ser83 r Phe (our type II pattern), and two isolates had Asp87 r Tyr, a different mutation at the same site rates, even with treatment courses as short as 2 and 3 days [4, 5, 16] . These drugs have been well tolerated, and concerns as our pattern III isolates. One further isolate had a combination of both mutations. The clinical response to treatment of these over possible toxicity to bones and joints in children have not been substantiated in careful studies with £2 years of followinfections was not described. Previous reports [8, 24] have described the development of up [6] . There are no safe, orally active alternatives that are as reliably effective.
resistance in Salmonella during treatment with fluoroquinolones. The NARST strains in the present study were isolated S. typhi isolates with reduced susceptibility [19, 20] or resistance to fluoroquinolones in vivo [21 -24] have been reported from blood cultures performed before treatment in the hospital, and none of the 20 patients whose NARST isolates were examon the Indian subcontinent, and quinolone resistance has now also emerged in Viet Nam. Strains of S. typhi isolated before ined by SSCP had a definite history of taking quinolones. One had taken ceftriaxone, one had taken co-trimoxazole, and 10 late 1993 were all susceptible to nalidixic acid; if they were not tested, the fluoroquinolone MICs for these strains were had taken an unknown drug. Urine samples from all 20 patients were tested on admission to the hospital, and only one of these lower than the range seen for the NARST isolates [25] . During 1993 and 1994 there was a localized outbreak of multidrugsamples showed antibiotic activity consistent with the use of a fluoroquinolone. This finding suggests infection with NARST, resistant typhoid in Tien Giang province in the Mekong Delta; 12 (41%) of 29 patients from Tien Giang province had a rather than mutation of the isolates during treatment.
Resistance to nalidixic acid, a first-generation DNA gyrase NARST isolate recovered, compared with 6 (5%) of 121 patients from other areas. Many of those infected were children, inhibitor, may be the harbinger of full fluoroquinolone resistance caused by an additional mutation in the same organism. which explains the younger age of the patients with NARST isolates (table 2). In 1995, 2.1% of isolates were nalidixic acid It has already been shown in E. coli that a double mutation in gyrA can increase the MIC of ciprofloxacin from 0.5 mg/mL resistant.
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